NCT01771107 (Clinical Trial / Brentuximab Vedotin / SGN-035)

Study Title
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (NCT01771107)

Trial Description
This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin (also known as SGN-035) and combination chemotherapy work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma.

Monoclonal antibody-drug conjugates or ADCs such as brentuximab vedotin can block cancer growth by finding cancer cells and causing them to die. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.

This trial is sponsored by the National Cancer Institute (NCI). [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
    • Other: Laboratory Biomarker Analysis
    • Other: Pharmacological Study
  • Phase: I & II
  • Estimated Enrollment: 51
  • Start: March 2013
  • Estimated Completion: June 2018 (Final data collection date for primary outcome measure)
  • Last verified: May 2015
  • Last updated: August 6, 2015

Study Schematic 

NCT01771107 (Clinical Trial / Brentuximab Vedotin)

Last Editorial review: July 21, 2016
Information based on (NIH/NCI) and other sources.